Y microsphere dosimetry navigator (RapidSphere) within a commercial platform (Velocity, Varian Medical Systems) was demonstrated for three microsphere cases that were imaged using optimized bremsstrahlung SPECT/CT. For each case, the 90 Y SPECT/CT was registered to follow-up diagnostic MR/CT using deformable image registration. The voxel-based dose distribution was computed using the local deposition method with known injected activity. The system allowed the visualization of the isodose distributions on any of the registered image datasets and the calculation of dose-volume histograms (DVHs). The dosimetric analysis illustrated high local doses that are characteristic of blood-flow directed brachytherapy. In the first case, the HCC mass demonstrated a complete response to treatment indicated by a necrotic region in follow-up MR imaging. This result was dosimetrically predicted since the gross tumor volume (GTV) was well covered by the prescription isodose volume (V150 Gy = 85%). The second case illustrated a partial response to treatment which was characterized by incomplete necrosis of an HCC mass and a remaining area of solid enhancement in follow-up MR imaging. This result was predicted by dosimetric analysis because the GTV demonstrated incomplete coverage by the prescription isodose volume (V470 Gy = 18%). The third case demonstrated extrahepatic activity. The dosimetry indicated that the prescription (125 Gy) isodose region extended outside of the liver into the duodenum (178 Gy maximum dose). This was predictive of toxicity as the patient later developed a duodenal ulcer. The ability to predict outcomes and complications using deformable image registration, calculated isodose distributions, and DVHs, points to the clinical utility of patient-specific dose calculations for 90 Y radioembolization treatment planning. which was previously demonstrated to be the most accurate when using SPECT imaging. 22 In this technique,
| INTRODUCTION

90
Y β-particles released by decay within a voxel deposit all energy locally with the same voxel.
This is an accurate approximation considering that the mean range of β-particles in tissue is 3.8 mm which is within the typical SPECT voxel size (4.8 mm cubic voxels in our study). The absorbed dose within a voxel is
where A = injected activity, LSF = lung shunt fraction, T 1/2 = 90 Y physical half-life (64.24 hours), E avg = average β-particle energy per disintegration (0.935 MeV), C voxel = SPECT counts within voxel, ΔV = voxel volume, ρ = tissue density, and C total = total SPECT counts within the patient (excluding the lungs). The derivation of Eq. (1) can be found in the Appendix. The only patient-specific parameters that had to be manually entered into the software prior to the dose calculation were the injected activity (GBq) and the lung shunt fraction (expressed as %). The default tissue density was set to that of soft tissue
). However, the software does provide the ability to enter tissue-specific densities for different contoured structures.
The last step in the 90 Y dosimetry navigator was to evaluate the isodose distributions superimposed on the deformably registered image datasets and generate dose-volume histograms (DVHs) for the contoured structures. It is important to note that the isodose distribution was not truncated within the liver contour, which allowed for the evaluation of extrahepatic dose.
The patient was a 64-year-old male with hepatitis C induced cirrhosis and HCC. This patient was determined to be unresectable due to the degree of cirrhosis and was referred for radionuclide therapy suspected at the time of arterial mapping due to the presence of omental vessels supplying the tumor that could not be catheterized.
The 6-week follow-up MR demonstrated that the GTV had a partial response to treatment. The mass was incompletely necrotic and there were still areas of solid enhancement. The ≥470 Gy dose region did not cover the contoured residual tumor (V470 Gy = 0%), however, the necrotic region was well covered (V470 Gy = 87%) which is apparent in the DVHs in Fig. 5 .
3.C | Case #3 -Extrahepatic activity
The patient was a 69-year-old male with HCC. The lung shunt fraction was determined to be 3.7% from the SPECT/CT study. A dose of 125 Gy was prescribed to the medial and lateral segments (1400 cc volume). The patient received 3.563 GBq of 90 Y using 3.2 million microspheres. 
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where E avg = average β-particle energy per disintegration, N = total number of disintegrations from a given amount of activity as a function of time within the voxel, integrated over all time.
But,
where A voxel = initial activity within the voxel, λ = decay constant And,
where T 1/2 = physical half-life (physical decay only, that is, no biological clearance is assumed in the case of Y-90 microspheres).
However,
where C voxel = SPECT counts within voxel, C Total = total SPECT counts within patient (excluding lungs), A Total = total activity within the patient (excluding lungs).
Finally,
where A = injected activity, LSF = lung shunt fraction Therefore, using Eqs. (A2), (A3), (A4), (A5), (A6), and (A7) into
Eq. (A1) we obtain:
